# DESCRIPTION

## BACKGROUND OF THE INVENTION

- define field of invention
- describe background art
- motivate need for invention

### Lung Bone-Specific Metastasis

- describe lung cancer
- classify lung cancer
- describe non-small-cell lung carcinoma
- describe small-cell lung carcinoma
- discuss prognosis
- describe metastasis
- describe skeletal metastasis
- discuss bone metastasis
- describe osteolytic lesions
- describe osteosclerotic lesions
- discuss molecular mechanisms
- describe genome-aberration-induced transcriptional changes
- discuss developmental history of cancer
- describe predisposing factors
- motivate need for understanding metastasis
- describe complex mechanisms of metastasis
- discuss tissue-specific metastatic cells
- describe acquired functions of metastatic cells
- motivate need for genetic markers
- describe current lack of markers
- motivate need for identifying new markers
- describe potential therapeutic opportunities

## BRIEF SUMMARY OF THE INVENTION

- identify role of MAF in lung cancer metastasis
- associate c-MAF with bone metastasis
- study c-MAF expression in patient cohorts
- correlate c-MAF expression with clinical parameters
- identify c-MAF as marker for prognosis
- associate 16q22-q24 amplification with metastasis
- describe in vitro method for diagnosis of metastasis
- quantify c-MAF gene expression level
- compare expression level to control sample
- diagnose metastasis based on expression level
- describe in vitro method for designing customized therapy
- quantify c-MAF gene expression level
- compare expression level to control sample
- determine therapy based on expression level
- describe in vitro method for designing customized therapy
- quantify c-MAF gene expression level in bone metastatic tumor
- compare expression level to control sample
- determine therapy based on expression level
- describe in vitro method for diagnosis of metastasis
- determine if c-MAF gene is amplified or translocated
- diagnose metastasis based on amplification or translocation
- describe in vitro method for predicting clinical outcome
- determine if c-MAF gene is amplified
- predict poor clinical outcome based on amplification
- describe use of c-MAF inhibitory agent
- describe kit for predicting bone metastasis
- quantify c-MAF expression level
- compare expression level to reference level
- determine therapy based on expression level

## DETAILED DESCRIPTION OF THE INVENTION

- introduce c-MAF gene and protein overexpression in lung cancer metastasis
- correlate c-MAF expression levels with clinical parameters of lung cancer
- describe c-MAF as a marker for diagnosis and prognosis of metastasis
- outline in vitro method for diagnosis of metastasis and prognosis of tendency to develop metastasis
- quantify c-MAF gene expression level in tumor sample
- compare expression level with control sample
- define c-MAF gene and its transcription factor function
- describe DNA sequence and coding sequence of c-MAF
- outline two messenger RNA transcribed from DNA sequence
- define metastasis and secondary tumor
- describe diagnosis of metastasis and prognosis of tendency to develop metastasis
- outline method of quantifying c-MAF gene expression level
- describe preferred embodiment of method using single marker
- define subject and patient
- describe clinical outcome and statistical significance
- outline methods for obtaining tumor sample
- describe methods for quantifying gene expression levels
- outline conventional methods for detecting and quantifying mRNA levels
- describe particular embodiment of quantifying c-MAF gene expression levels
- define functionally equivalent variant of c-MAF protein
- identify variants using methods
- determine sequence similarity
- quantify c-MAF protein expression level
- describe detection and quantification methods
- list antibodies and reagents
- quantify c-MAF protein levels in particular embodiments
- describe exosomes and circulating DNA
- isolate exosomes
- describe first method of the invention
- compare c-MAF gene expression levels
- diagnose metastasis or tendency to develop metastasis
- determine reference sample or control sample
- describe considerations for determining reference concentration
- establish reference value using ROC curve
- assign increased or reduced expression levels
- describe increased expression levels
- define positive diagnosis for metastasis
- describe osteolytic bone metastasis
- define greater tendency to develop metastasis
- describe prediction of tendency to metastasize
- describe statistical significance
- define agent for avoiding or preventing bone degradation
- define c-MAF inhibitory agent
- identify c-MAF gene expression inhibitors
- define Mammalian target of rapamycin (mTOR)
- define mTor inhibitor
- describe mTor inhibitors
- describe mTor gene expression inhibition
- describe direct inhibition of mTor protein activity
- describe mTor inhibitors with multiple targets
- define Src
- define Src inhibitor
- define COX-2
- define COX-2 inhibitor
- define outcome
- define predicting
- define good prognosis
- define poor prognosis
- define reference value
- define treatment
- define sample
- define expression level
- define gene copy number
- define increased expression level
- define probe
- define tag
- define translocation
- describe polyploid
- describe whole genome sequencing
- describe Src role
- describe COX-2 role
- define exome sequencing
- define tumor tissue sample
- define osteolytic bone metastasis
- introduce method for designing customized therapy
- quantify c-MAF gene expression level
- compare expression level with control sample
- determine therapy based on expression level
- describe metastasis treatment options
- describe systemic treatments
- describe chemotherapy
- describe hormone therapy
- describe immunotherapy
- describe Alpharadin treatment
- describe mTor inhibitor treatment
- list mTor inhibitors
- describe Src kinase inhibitor treatment
- list Src kinase inhibitors
- describe use of mTor inhibitor in combination therapy
- describe use of Src kinase inhibitor in combination therapy
- describe use of mTor inhibitor in advanced lung cancer
- describe use of Src kinase inhibitor in advanced lung cancer
- describe use of Src kinase inhibitor in SRS+ patients
- describe use of Src kinase inhibitor in ER- patients
- describe identification of mTor inhibitors
- describe identification of Src kinase inhibitors
- describe treatment of bone metastasis
- describe treatment of osteolytic metastasis
- describe prevention of bone degradation
- describe prevention of metastasis
- introduce COX-2 inhibitors
- list COX-2 inhibitors
- describe use of COX-2 inhibitors to prevent metastasis
- describe use of COX-2 inhibitors in combination with second treatment
- list second treatments
- introduce treatment agents for avoiding bone degradation
- describe parathyroid hormone inhibitors
- describe strontium ranelate
- describe estrogen receptor modulators
- describe calcitonin
- describe bisphosphonates
- describe cathepsin K inhibitors
- describe DKK-1 inhibitors
- describe dual MET and VEGFR2 inhibitors
- describe RANKL inhibitors
- describe RANK protein
- describe osteoprotegerin
- describe RANKL-specific antisense molecules
- describe ribozymes
- describe anti-RANKL antibodies
- describe preparation of polyclonal antibodies
- describe preparation of monoclonal antibodies
- describe antibody fragments
- describe nanobodies
- describe structure of nanobodies
- describe VHH domain
- describe use of nanobodies as therapeutic antibodies
- describe other treatment agents
- describe Denosumab
- describe Zometa
- describe Carbozantinib or Cabozantinib
- describe Antibody or peptide blocking PTHLH or PTHrP
- describe other COX-2 inhibitors
- describe other treatment agents for avoiding bone degradation
- describe other dual MET and VEGFR2 inhibitors
- conclude treatment agents
- specify RANKL inhibitors
- describe embodiments
- list bone degradation agents
- describe CCR5 antagonist embodiments
- specify dual MET and VEGFR2 inhibitor embodiments
- outline combined treatment options
- introduce lung cancer patients
- motivate customized therapy
- outline third method of invention
- define terms and expressions
- describe preferred embodiments
- determine susceptibility to therapy
- define agent for avoiding or preventing bone degradation
- illustrate examples of agents
- describe parathyroid hormone
- describe strontium ranelate
- describe estrogen receptor modulators
- describe calcitonin
- describe bisphosphonates
- describe cathepsin K inhibitors
- describe DKK-1 inhibitors
- describe dual MET and VEGFR2 inhibitors
- describe RANKL inhibitors
- describe RANK protein
- describe osteoprotegerin
- describe RANKL-specific antisense molecules
- describe ribozymes
- describe specific anti-RANKL antibodies
- describe specific anti-RANKL nanobodies
- describe preferred RANKL inhibitors
- describe Denosumab
- describe ALX-0141
- describe preferred agents preventing bone degradation
- describe CCR5 antagonists
- describe Maraviroc
- describe Vicriviroc
- describe Aplaviroc
- describe spiropiperidine CCR5 antagonists
- describe INCB009471
- describe dual MET and VEGFR2 inhibitors
- describe mTor inhibitors
- describe specific mTor inhibitors
- introduce Src kinase inhibitors
- list Src kinase inhibitors
- describe use of Src kinase inhibitors to prevent or inhibit metastasis
- describe use of Src kinase inhibitors to treat or prevent or inhibit metastasis in a patient with advanced lung cancer
- describe use of Src kinase inhibitors in combination with a second treatment
- introduce COX-2 inhibitors
- list COX-2 inhibitors
- describe use of COX-2 inhibitors to prevent or inhibit metastasis
- describe use of COX-2 inhibitors to treat or prevent or inhibit metastasis in a patient with advanced lung cancer
- describe use of COX-2 inhibitors in combination with a second treatment
- introduce Radium 223 therapy
- describe properties of Radium 223
- describe use of Radium 223 to kill cancer cells
- introduce bisphosphonates
- describe use of bisphosphonates to prevent bone degradation
- introduce combined treatment
- describe combined treatment with multiple agents
- introduce method of diagnosis or prognosis of metastasis in lung cancer
- describe determining amplification of c-MAF gene
- describe use of amplification of c-MAF gene for diagnosis of metastasis
- describe use of amplification of c-MAF gene for prognosis of tendency to develop metastasis
- describe determining degree of amplification of c-MAF gene
- describe use of chromosome region containing c-MAF gene
- describe use of probe specific for c-MAF gene
- describe first step of diagnosis/prognosis method
- describe comparing amplification of c-MAF gene in tumor sample with control sample
- describe use of NSCLC in diagnosis/prognosis method
- describe terms used in diagnosis/prognosis method
- describe applicability of terms to fourth method of invention
- conclude diagnosis/prognosis method
- define amplification of a gene
- describe gene copy number
- introduce c-MAF gene copy number determination
- describe control sample
- explain increased gene copy number
- describe in situ hybridization
- describe fluorescence in situ hybridization
- describe chromogenic in situ hybridization
- describe silver in situ hybridization
- describe polymerase chain reaction
- introduce method of prognosis of metastasis
- describe determining c-MAF gene copy number
- compare with control sample
- determine bone metastasis
- describe osteolytic bone metastasis
- introduce method of prognosis of metastasis based on translocation
- describe determining translocation of c-MAF gene
- describe translocation of chromosome region
- describe probe specific for translocation
- describe dual color probe
- describe dual fusion probe
- describe dual color, dual fusion probe
- describe separate probes
- introduce Vysis LSI IGH/MAF Dual Color dual fusion probe
- introduce Kreatech diagnostics MAF/IGH gt(14;16) Fusion probe
- introduce other probes
- describe fluorophore on probe
- describe specific fluorophores
- describe DAPI counterstain
- introduce method of prognosis of bone metastasis
- describe determining c-MAF gene copy number
- compare with control sample
- determine bone metastasis
- describe osteolytic metastasis
- introduce average level
- describe standard deviation
- determine c-MAF gene expression level
- compare with average level
- determine bone metastasis
- describe methods for determining translocation
- describe whole genome sequencing
- describe exome sequencing
- describe PCR-derived technology

### Therapeutic Methods of the Invention

- treat bone metastasis using c-MAF inhibitory agents
- use c-MAF inhibitory agent for manufacturing medicament
- method for treating bone metastasis from lung cancer
- prevent or reduce risk of bone metastasis in lung cancer patients
- use c-MAF gene expression inhibitory agent in medicinal product
- define c-MAF inhibitory agent
- identify c-MAF gene expression inhibitors
- describe antisense oligonucleotides
- administer antisense construct as expression plasmid
- generate antisense oligonucleotide probes ex vivo
- modify oligonucleotides for stability and hybridization capacity
- design oligonucleotides for antisense therapy
- conjugate oligonucleotides to other molecules
- use modified base groups in antisense oligonucleotides
- use modified sugar groups in antisense oligonucleotides
- use peptide nucleic acid (PNA) oligomers
- use alpha-anomeric oligonucleotides
- use antisense oligonucleotides complementary to coding region
- use antisense oligonucleotides complementary to non-translated region
- use recombinant DNA construct with antisense oligonucleotide
- direct deoxyribonucleotide sequences to form triple helix structures
- describe siRNA
- synthesize siRNA chemically or in vitro
- synthesize siRNA in vivo in target cells
- describe siRNA structure and function
- modify siRNA with chemical modifications
- use vectors for expressing siRNA
- describe promoters for expressing siRNA
- use convergent and divergent transcription vectors
- describe shRNA
- generate shRNA intracellularly
- encode shRNA by plasmids or viruses
- describe vectors for expressing shRNA
- design siRNA and shRNA
- identify AA(N19)TT motifs in c-MAF gene sequence
- select siRNA with high G/C content
- describe c-MAF specific siRNA sequences
- describe DNA enzymes
- design DNA enzymes to inhibit c-MAF gene expression
- describe ribozymes for catalytically cleaving target mRNA
- introduce therapeutic methods of the invention
- describe ribozymes used in the invention
- describe formation of ribozymes
- describe distribution of ribozymes to cells
- introduce inhibitory antibodies
- describe preparation of inhibitory antibodies
- describe types of inhibitory antibodies
- describe selection of inhibitory antibodies
- introduce inhibitory peptides
- describe inhibitory peptides
- introduce negative c-MAF dominants
- describe negative c-MAF dominants
- describe variants of negative c-MAF dominants
- describe promoters for regulating transcription
- describe constitutive promoters
- describe inducible promoters
- describe vectors for expressing polynucleotides
- describe types of vectors
- introduce other inhibitory compounds
- describe other inhibitory compounds
- introduce pharmaceutical composition
- describe pharmaceutical composition
- describe carriers for pharmaceutical composition
- describe pharmaceutical dosage forms
- describe administration routes
- describe nucleic acid administration
- describe liposome conjugation
- describe viral vector administration
- describe dose and frequency of administration
- describe treatment or prevention of bone degradation
- describe use of agent for preventing bone degradation
- describe method of preventing bone degradation
- describe agents for preventing bone degradation
- describe control sample
- describe methods for determining elevated c-MAF levels
- describe combined treatment
- describe administration of agents for preventing bone degradation

### Kits of the Invention

- define kit for predicting bone metastasis
- define kit for predicting clinical outcome
- define kit for determining therapy
- describe kit components

### Method for Typing a Sample of a Subject Suffering Lung Cancer.

- outline method for typing sample
- quantify expression level of c-MAF
- compare expression level to reference
- provide prognostic information

## EXAMPLES

### Example 1

- test c-MAF in lung cancer patient cohorts
- correlate c-MAF expression with clinical parameters
- analyze patient cohort I
- perform statistical analysis
- determine association between c-MAF expression and bone relapse
- describe patient cohort II

### Example 2

- correlate c-MAF expression with metastasis
- perform statistical analysis

### Example 3

- perform immunohistochemistry analysis
- score c-MAF immunostaining
- evaluate prognostic and predictive value of c-MAF
- determine c-MAF protein levels
- analyze spectral data
- set computer-aided threshold
- summarize results in Table 3

### Example 4

- determine 16q22-q24 chromosome amplification
- use FISH probe to measure 16q22-24 region
- evaluate prognostic and predictive value of 16q22-24 CNA gain
- determine 16q23 and 14q32 copies
- calculate odds ratio of risk of bone metastasis
- summarize results in Tables 4 and 5

